» Articles » PMID: 38937969

An Aptamer-mediated Base Editing Platform for Simultaneous Knockin and Multiple Gene Knockout for Allogeneic CAR-T Cells Generation

Abstract

Gene editing technologies hold promise for enabling the next generation of adoptive cellular therapies. In conventional gene editing platforms that rely on nuclease activity, such as clustered regularly interspaced short palindromic repeats CRISPR-associated protein 9 (CRISPR-Cas9), allow efficient introduction of genetic modifications; however, these modifications occur via the generation of DNA double-strand breaks (DSBs) and can lead to unwanted genomic alterations and genotoxicity. Here, we apply a novel modular RNA aptamer-mediated Pin-point base editing platform to simultaneously introduce multiple gene knockouts and site-specific integration of a transgene in human primary T cells. We demonstrate high editing efficiency and purity at all target sites and significantly reduced frequency of chromosomal translocations compared with the conventional CRISPR-Cas9 system. Site-specific knockin of a chimeric antigen receptor and multiplex gene knockout are achieved within a single intervention and without the requirement for additional sequence-targeting components. The ability to perform complex genome editing efficiently and precisely highlights the potential of the Pin-point platform for application in a range of advanced cell therapies.

Citing Articles

Revolutionizing Immunotherapy: Unveiling New Horizons, Confronting Challenges, and Navigating Therapeutic Frontiers in CAR-T Cell-Based Gene Therapies.

Srivastava S, Tyagi A, Pawar V, Khan N, Arora K, Verma C Immunotargets Ther. 2024; 13:413-433.

PMID: 39219644 PMC: 11365499. DOI: 10.2147/ITT.S474659.

References
1.
Tan J, Zhang F, Karcher D, Bock R . Expanding the genome-targeting scope and the site selectivity of high-precision base editors. Nat Commun. 2020; 11(1):629. PMC: 6994485. DOI: 10.1038/s41467-020-14465-z. View

2.
Barkal A, Weiskopf K, Kao K, Gordon S, Rosental B, Yiu Y . Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2017; 19(1):76-84. PMC: 5832354. DOI: 10.1038/s41590-017-0004-z. View

3.
Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H . Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8(5):765-72. DOI: 10.1093/intimm/8.5.765. View

4.
Grunewald J, Zhou R, Iyer S, Lareau C, Garcia S, Aryee M . CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat Biotechnol. 2019; 37(9):1041-1048. PMC: 6730565. DOI: 10.1038/s41587-019-0236-6. View

5.
Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View